Neil Kumar Bridge Bio Pharma, Inc. (BBIO) insider trading activity

Neil Kumar is Chief Executive Officer of BridgeBio Pharma, Inc.. Currently has a direct ownership of 228,776 shares of BBIO, which is worth approximately $15.2 Million. The most recent transaction as insider was on Dec 15, 2025, when has been sold 30,011 shares (Common Stock) at a price of $74.92 per share, resulting in proceeds of $2,248,424. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 229K

2.55% 3M change

8.06% 12M change

Total Value Held $15.2 Million

Neil Kumar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 15 2025	SELL Open market or private sale	$2,248,424 $74.92 p/Share	30,011 Reduced 11.6%	228,776 Common Stock
Dec 12 2025	SELL Payment of exercise price or tax liability	$2,326,944 $75.15 p/Share	30,964 Reduced 10.69%	258,787 Common Stock
Dec 12 2025	BUY Exercise of conversion of derivative security	-	60,975 Added 17.39%	289,751 Common Stock
Nov 20 2025	SELL Open market or private sale	$1,722,634 $65.86 p/Share	26,156 Reduced 10.26%	228,776 Common Stock
Nov 16 2025	SELL Payment of exercise price or tax liability	$2,181,243 $66.39 p/Share	32,855 Reduced 11.42%	254,932 Common Stock
Nov 16 2025	BUY Exercise of conversion of derivative security	-	64,697 Added 18.35%	287,787 Common Stock
Aug 20 2025	SELL Open market or private sale	$1,282,428 $49.03 p/Share	26,156 Reduced 10.49%	223,090 Common Stock

Aug 16 2025	SELL Payment of exercise price or tax liability	$1,686,118 $51.32 p/Share	32,855 Reduced 11.65%	249,246 Common Stock
Aug 16 2025	BUY Exercise of conversion of derivative security	-	64,697 Added 18.66%	282,101 Common Stock
May 19 2025	SELL Open market or private sale	$877,272 $33.54 p/Share	26,156 Reduced 10.74%	217,404 Common Stock
May 16 2025	SELL Payment of exercise price or tax liability	$1,111,779 $33.84 p/Share	32,854 Reduced 11.89%	243,560 Common Stock
May 16 2025	BUY Exercise of conversion of derivative security	-	64,696 Added 18.97%	276,414 Common Stock
Feb 19 2025	SELL Open market or private sale	$1,146,588 $36.35 p/Share	31,543 Reduced 12.97%	211,718 Common Stock
Feb 16 2025	SELL Payment of exercise price or tax liability	$837,460 $34.9 p/Share	23,996 Reduced 8.98%	243,261 Common Stock
Feb 16 2025	BUY Exercise of conversion of derivative security	-	55,539 Added 17.21%	267,257 Common Stock
Dec 24 2024	SELL Bona fide gift	-	4,685,725 Reduced 95.68%	211,718 Common Stock
Nov 19 2024	SELL Open market or private sale	$618,443 $22.58 p/Share	27,389 Reduced 0.56%	4,897,443 Common Stock
Nov 16 2024	SELL Payment of exercise price or tax liability	$667,670 $23.72 p/Share	28,148 Reduced 0.57%	4,924,832 Common Stock
Nov 16 2024	BUY Exercise of conversion of derivative security	-	55,537 Added 1.11%	4,952,980 Common Stock
Aug 19 2024	SELL Open market or private sale	$678,151 $24.76 p/Share	27,389 Reduced 0.56%	4,897,443 Common Stock
Aug 16 2024	SELL Payment of exercise price or tax liability	$686,811 $24.4 p/Share	28,148 Reduced 0.57%	4,924,832 Common Stock
Aug 16 2024	BUY Exercise of conversion of derivative security	-	55,537 Added 1.11%	4,952,980 Common Stock
May 16 2024	SELL Payment of exercise price or tax liability	$954,417 $31.04 p/Share	30,748 Reduced 0.62%	4,897,443 Common Stock
May 16 2024	BUY Exercise of conversion of derivative security	-	60,667 Added 1.22%	4,928,191 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$1,783,177 $37.21 p/Share	47,922 Reduced 0.97%	4,867,524 Common Stock

Neil Kumar

Chief Executive Officer

Palo Alto, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BBIO shares.

Notify only if

Value

Insider Trading

Get notified when an Bridge Bio Pharma, Inc. insider buys or sells BBIO shares.

Notify only if

Operation

Value

Type

News

Receive news related to BridgeBio Pharma, Inc.

Track Activities on BBIO

Account